Helicobacter Pylori Infection, Parkinson's Disease
Conditions
Keywords
Parkinson's Disease, Helicobacter pylori infection
Brief summary
It has been hypothesized, based on epidemiological observations, that Helicobacter pylori (HP) infection may play a role in the pathogenesis of Parkinson's Disease (PD). Previous studies have also shown that HP eradication therapy may result in improvements in levodopa pharmacokinetics and motor fluctuations. This study aims to examine the effects of HP eradication, using a double-blind randomized placebo-controlled trial design in a relatively large cohort of patients. Outcomes of interest include motor function, gastrointestinal symptoms and health-related quality of life. The investigators hypothesize that HP eradication will lead to improvements in motor function. The primary outcome of interest is the ON-medication Unified PD Rating Scale (UPDRS) Part III score at 3 months. Secondary outcomes include Purdue Pegboard Score, Timed Test of Gait, Dyskinesia and Bradykinesia scores measured by Parkinson's Kinetigraph (PKG), Leeds Dyspepsia Questionnaire (LDQ), Parkinson's Disease Questionnaire (PDQ-39), UPDRS Part I, Part II and Part IV; and Montreal Cognitive Assessment (MOCA).
Interventions
DRUGPlacebo
Sponsors
University of Malaya
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged ≥18 years 2. Provision of written informed consent 3. Clinical diagnosis of Parkinson's Disease (PD) assigned by a consultant neurologist
Exclusion criteria
1. History of previous gastric or major abdominal/pelvic surgery 2. History of previous eradication therapy for Helicobacter pylori 3. Antibiotic use in the preceding four weeks or use of anti-acid/prokinetics/laxatives in the preceding one week prior to breath test 4. Recent initiation of dopaminergic medications (within the last three months) or recent adjustment of dopaminergic medications (within the last one month) 5. History of functional neurosurgery for PD 6. No concomitant neurologic disease except PD 7. Medical condition that prevents reliable completion of questionnaire
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| On-medication MDS-UPDRS Part III score | at 3 months after randomisation |
Secondary
| Measure | Time frame |
|---|---|
| On-medication Pegboard Score | at 3 months and 1 year post randomisation |
| On-medication Timed Gait Score | at 3 months and 1 year post randomisation |
| Parkinson's Kinetigraph (PKG) Bradykinesia and Dyskinesia Scores | at 3 months and 1 year post randomisation |
| UPDRS Part IV | at 3 months and 1 year post randomisation |
| On-medication UPDRS Part III score | at 1 year post randomisation |
| UPDRS Part I | at 3 months and 1 year post randomisation |
| Montreal Cognitive Assessment Score | at 3 months and 1 year post randomisation |
| Leeds Dyspepsia Questionnaire | at 3 months and 1 year post randomisation |
| Parkinson Disease Questionnaire (PDQ-39) | at 3 months and 1 year post randomisation |
| UPDRS Part II | at 3 months and 1 year post randomisation |
Countries
Malaysia
Outcome results
None listed